These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25535814)

  • 41. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
    Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
    BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
    Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
    Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
    Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.
    Habineza Ndikuyeze G; Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Flood P; Krick E; Propert KJ; Mason NJ
    PLoS One; 2014; 9(5):e95404. PubMed ID: 24798348
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
    Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
    Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
    Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J
    Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
    Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
    Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
    Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY
    Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Primary ocular adnexal lymphoproliferative lesions: clinicopathologic features and genetic alterations].
    Dong LN; Liu HG; Jin HS; Ye HT; Gao ZF; Zhou XG; Dong GH; Zhang DD; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2008 Dec; 37(12):809-14. PubMed ID: 19159526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
    Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
    Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
    Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
    Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
    Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.
    Wang L; Zhao WL; Yan JS; Liu P; Sun HP; Zhou GB; Weng ZY; Wu WL; Weng XQ; Sun XJ; Chen Z; Sun HD; Chen SJ
    Cell Death Differ; 2007 Feb; 14(2):306-17. PubMed ID: 16778832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.